HCA Healthcare’s third quarter results modestly exceeded Wall Street’s expectations, driven by continued growth in demand for its hospital services and improvements in core cost management initiatives. CEO Samuel Hazen attributed the company’s performance to 22 consecutive quarters of volume growth, highlighting that “insured volumes grew faster in the quarter than in the first half of the year.” Management also pointed to an increase in revenue per adjusted admission for insured patients and incremental net benefits from Medicaid supplemental payment programs as key factors offsetting pressure from a rising uninsured patient population. CFO Michael Marks underscored that strong operating discipline led to essentially flat costs per equivalent admission versus the prior year, despite ongoing challenges in payer mix and elective surgical volumes.
Is now the time to buy HCA? Find out in our full research report (it’s free for active Edge members).
HCA Healthcare (HCA) Q3 2026 highlights:
- Revenue $19.85 billion vs S&P analysts’ estimates of $19.28 billion (3.6% year-on-year growth, 3% beat)
- EPS (GAAP) $7.27 vs analyst estimates of $6.79 (7% beat)
- Adjusted EBITDA $3.92 billion vs analyst estimates of $3.74 billion (19.7% margin, 4.9% beat)
- Revenue guidance The company reconfirmed its revenue guidance for the full year of $78.25 billion at the midpoint
- GAAP EPS guidance $29.60 at the midpoint for the full year, roughly in line with what analysts were expecting
- EBITDA guidance $15.75 billion at the midpoint for the full year, in line with analyst expectations
- Operating margin 15.1%, in line with the same quarter last year
- Market capitalization $100.3 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from HCA Healthcare’s Q3 earnings call
- Albert Rice (UBS) asked about the magnitude of public exchange headwinds and expected cost savings from resiliency programs. CFO Michael Marks reiterated planning was ongoing but emphasized resiliency is now a core, ongoing strategic initiative.
- Ann Hynes (Mizuho) inquired about potential benefits from the 340B reallocation in the proposed Medicare OPPS rule. Marks said HCA would benefit but has not yet sized the impact, pending final rulemaking.
- Ben Hendrix (RBC Capital Markets) asked if pent-up demand could drive elective surgery growth next year. CEO Samuel Hazen explained that while emergent cases are strong, elective procedures remain pressured by coverage and affordability, with no plans to forecast a recovery until more data is available.
- Sarah James (Cantor Fitzgerald) questioned how much elective surgery volume pressure is due to exchange coverage losses versus affordability. Hazen said coverage dynamics are the largest factor but affordability pressures also play a role, with no outsized tailwind expected in Q4.
- Craig Hettenbach (Morgan Stanley) probed applications of the resiliency program. Marks detailed four focus areas: revenue integrity, asset optimization, variable cost control, and fixed cost management, with ongoing digital transformation supporting future gains.
Catalysts in upcoming quarters
Looking forward, the StockStory team will be monitoring (1) the pace and sustainability of insured volume growth across key markets, (2) the company’s ability to manage ongoing shifts in payer mix and absorb lower Medicaid supplemental payments, and (3) whether digital transformation and resiliency initiatives deliver further cost efficiencies. We also see updates on surgery trends and policy changes as important markers.
HCA Healthcare currently trades at $470.77, up from $465.26 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
Our favorite stocks right now
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
